Completed

Cross-sectional Study to Assess the Handling , Patient Satisfaction, and Preference for Inhalation Devices in Patients With Chronic Obstructive Pulmonary Disease (COPD).

What is being collected

Device Data

+ device Data

Collected at a single point in time - Cross-sectional

Device

Who is being recruted

Chronic Disease+5

+ Lung Diseases

+ Lung Diseases, Obstructive

Over 18 Years

+5 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Observational

Study Start: March 2013

See protocol details

Summary

Principal SponsorBoehringer Ingelheim

Last updated: March 26, 2015

Sourced from a government-validated database.Claim as a partner

Study start date: March 1, 2013

Actual date on which the first participant was enrolled.

Purpose: Study Design:

NCT01810692

Principal SponsorBoehringer Ingelheim

Last updated: March 26, 2015

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

150 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Chronic DiseaseLung DiseasesLung Diseases, ObstructivePathologic ProcessesRespiratory Tract DiseasesPathological Conditions, Signs and SymptomsDisease AttributesPulmonary Disease, Chronic Obstructive

Criteria

2 inclusion criteria required to participate

Adult male or female patients with chronic obstructive pulmonary disease (COPD) for less than a year who follow usual clinical practice of the participant sites and who are on treatment with Spiriva Respimat, Hirobriz Breezhaler / Onbrez Breezhaler / Oslif Breezhaler for at least of 3 months but not more than maximum of 6 months before the informed consent date

All patients must sign an informed consent consistent with International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines prior to participation in the study and conducting any study procedures

3 exclusion criteria prevent from participating

Patients who are treated simultaneously with both respiratory medications (Spiriva Respimat and Hirobriz Breezhaler / Onbrez Breezhaler / Oslif Breezhaler)

Previously included in this study or currently participating in another interventional study

Visual, cognitive, or motor impairment that as judged by the investigator does not allow the patient to independently read and complete the questionnaire

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Treatment Groups

Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group

Treatment Groups

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 15 locations

Boehringer Ingelheim Investigational Site 13

A Coruña, SpainOpen Boehringer Ingelheim Investigational Site 13 in Google Maps

Boehringer Ingelheim Investigational Site 5

Barcelona, Spain

Boehringer Ingelheim Investigational Site 6

Barcelona, Spain

Boehringer Ingelheim Investigational Site 8

Barcelona, Spain

Completed15 Study Centers